Zyprexa news | Breaking Zyprexa news

Lilly profit beats forecasts, helped by lower tax

...The drug's sales fell 15 percent in the United States, but grew 6 percent in overseas markets.Sales of Strattera, Lilly's treatment for attention deficit disorder, slipped 8 percent to $168 million, hurt by the recent placement of a prominent warning inside the packaging that it may increase the risk of suicidal thoughts among children and adolescents.Sales of Lilly's diabetes products rose 11 percent to $750 million, helped by the launch of Byetta and higher prices for older treatments.Injectable osteoporosis drug Forteo jumped 59 percent to $118 million, while sales of older treatment Evista rose 3 percent to $265 million.

Sales of Alimta, a new treatment for lung cancer, rose 86 percent to $136 million.Sales of Cialis, the anti-impotence pill sold in partnership with ICOS Corp.

(ICOS.O: Quote, Profile, Research), rose 38 percent to $211 million.

Pfizer Inc.'s (PFE.N: Quote, Profile, Research) rival Viagra suffered a sales decline in the quarter, hurt by competition from Lilly's longer-acting product.Lilly reaffirmed its 2006 earnings forecast of $3.10 to $3.20 per share, first delivered last month and excluding special items.

It is in line with the average estimate of $3.13 among analysts polled by Reuters Estimates.The company forecast first-quarter earnings of 73 cents to 75 cents per share, representing growth of 7 percent to ...

Zyprexa

News

Advertisers:

Lilly profit beats forecasts, helped by lower tax